Literature DB >> 35089089

The Development of 18F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1.

Hsiaoju S Lee1, Sally W Schwarz1, Erin K Schubert1, Delphine L Chen1, Robert K Doot1, Mehran Makvandi1, Lilie L Lin1, Elizabeth S McDonald1, David A Mankoff1, Robert H Mach1.   

Abstract

Fluorine 18 (18F) fluorthanatrace (18F-FTT) is a PET radiotracer for imaging poly (adenosine diphosphate-ribose) polymerase-1 (PARP-1), an important target for a class of drugs known as PARP inhibitors, or PARPi. This article describes the stepwise development of this radiotracer from its design and preclinical evaluation to the first-in-human imaging studies and the initial validation of 18F-FTT as an imaging-based biomarker for measuring PARP-1 expression levels in patients with breast and ovarian cancer. A detailed discussion on the preparation and submission of an exploratory investigational new drug application to the Food and Drug Administration is also provided. Additionally, this review highlights the need and future plans for identifying a commercialization strategy to overcome the major financial barriers that exist when conducting the multicenter clinical trials needed for approval in the new drug application process. The goal of this article is to provide a road map that scientists and clinicians can follow for the successful clinical translation of a PET radiotracer developed in an academic setting. Keywords: Molecular Imaging-Cancer, PET, Breast, Genital/Reproductive, Chemistry, Radiotracer Development, PARPi, 18F-FTT, Investigational New Drug © RSNA, 2022.

Entities:  

Keywords:  18F-FTT; Breast; Chemistry; Genital/Reproductive; Investigational New Drug; Molecular Imaging-Cancer; PARPi; PET; Radiotracer Development

Mesh:

Substances:

Year:  2022        PMID: 35089089      PMCID: PMC8830434          DOI: 10.1148/rycan.210070

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN: 2638-616X


  41 in total

Review 1.  Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.

Authors:  Ling Wang; Qi Wang; Yangchun Xu; Manhua Cui; Liying Han
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

2.  The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies.

Authors:  Sally W Schwarz; Reiko Oyama
Journal:  J Nucl Med       Date:  2015-03-12       Impact factor: 10.057

3.  Extending the scope of PARP inhibitors in ovarian cancer.

Authors:  Jonathan A Ledermann
Journal:  Lancet Oncol       Date:  2019-03-14       Impact factor: 41.316

4.  Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.

Authors:  Dong Zhou; Wenhua Chu; Jinbin Xu; Lynne A Jones; Xin Peng; Shihong Li; Delphine L Chen; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2014-01-24       Impact factor: 3.641

Review 5.  Multimodality Imaging of Prostate Cancer.

Authors:  Soleen Ghafoor; Irene A Burger; Alberto H Vargas
Journal:  J Nucl Med       Date:  2019-09-03       Impact factor: 10.057

6.  PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.

Authors:  Loren S Michel; Samantha Dyroff; Frank J Brooks; Katherine J Spayd; Sora Lim; Jacquelyn T Engle; Sharon Phillips; Benjamin Tan; Andrea Wang-Gillam; Christopher Bognar; Wenhua Chu; Dong Zhou; Robert H Mach; Richard Laforest; Delphine L Chen
Journal:  Radiology       Date:  2016-11-14       Impact factor: 11.105

7.  A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

Authors:  Mehran Makvandi; Austin Pantel; Lauren Schwartz; Erin Schubert; Kuiying Xu; Chia-Ju Hsieh; Catherine Hou; Hyoung Kim; Chi-Chang Weng; Harrison Winters; Robert Doot; Michael D Farwell; Daniel A Pryma; Roger A Greenberg; David A Mankoff; Fiona Simpkins; Robert H Mach; Lilie L Lin
Journal:  J Clin Invest       Date:  2018-04-16       Impact factor: 14.808

8.  Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.

Authors:  Michael S Hofman; W F Eddie Lau; Rodney J Hicks
Journal:  Radiographics       Date:  2015 Mar-Apr       Impact factor: 5.333

9.  Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo.

Authors:  Redmond-Craig Anderson; Mehran Makvandi; Kuiying Xu; Brian P Lieberman; Chenbo Zeng; Daniel A Pryma; Robert H Mach
Journal:  Nucl Med Biol       Date:  2016-08-12       Impact factor: 2.408

Review 10.  Bringing New PET drugs to clinical practice - a regulatory perspective.

Authors:  Joseph C Hung
Journal:  Theranostics       Date:  2013-11-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.